Trinity Biotech announced that its New York based reference laboratory, Immco Diagnostics, has applied for a Proprietary Laboratory Analyses, PLA, code for its Early Sjogrens Syndrome Test Panel, to allow for an optimized market access strategy to deliver broader patient access and improved profitability. Subject to approval, Trinity expects the PLA code for the Early Sjogrens Syndrome Test Panel to become effective in Q3 2024, which should allow Immco Diagnostics to implement a further optimised market access strategy, aimed at delivering better patient access, while affording improved profitability for both Immco Diagnostics and our commercialization partners.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on TRIB:
- Trinity Biotech sees Q4 revenue $13M-$14M
- Trinity Biotech reports Q3 EPS (17.5c) vs. (23.5c) last year
- Trinity Biotech Announces Q3 2023 Financial Results & Business Update
- Trinity Biotech to acquire assets from Waveform for $12.5M, 9M ADSs
- Trinity Biotech Announces Acquisition of the CGM Assets of Waveform Technologies, Inc.
